01.07.13
Standard launched to drive up outcomes for arthritis
A new quality standard for the diagnosis and treatment of rheumatoid arthritis has been published by NICE to improve access to care and prevent long-term disability.
The initial cost savings predicted in primary care are over £3m through reduced GP visits and fewer unnecessary diagnostic tests. It is estimated that 422,000 people have rheumatoid arthritis in the UK, but resources vary across the country.
Only 60% of people who visit their GP with symptoms are referred to a specialist within three months, and delays in treatment can have a dramatic effect on the patient. The standard recommends patients should be referred within three weeks.
The quality standard was created in association with the British Society for Rheumatology (BSR).
Dr Robert Moots, adviser on the NICE board for the quality standards, said: “The NICE quality standards for rheumatoid arthritis are based on the best scientific evidence and will ensure that patients receive the best treatment wherever they live. Rheumatoid arthritis patients should expect great outcomes today, compared to the past.”
Dr Chris Deighton, president of the BSR, said: “I welcome the quality standards because they will help patients, commissioners and specialist providers to know precisely what they should expect from high quality rheumatoid arthritis services.”
Tell us what you think – have your say below, or email us directly at [email protected]